Givosiran holds promise for rare genetic disorder
30 Jul 2020
bởiAudrey Abella
Patients with acute intermittent porphyria (AIP) – the most common subtype of acute hepatic porphyria (AHP) – had significantly reduced attack rates, as well as improvements in other parameters, with givosiran, the phase III ENVISION trial has shown.
